ADLAI NORTYE LTD. - AMERICAN DEPOSITARY SHARES

Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025

10 апр 2025 07:00:00 Источник Nasdaq GlobeNewswire

Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress

08 авг 2024 07:30:00 Источник Nasdaq GlobeNewswire

Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

08 авг 2024 07:00:01 Источник Nasdaq GlobeNewswire

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

23 май 2024 20:03:04 Источник Nasdaq GlobeNewswire

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

22 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

29 мар 2024 05:00:00 Источник Nasdaq GlobeNewswire

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

17 ноя 2023 06:30:00 Источник Nasdaq GlobeNewswire

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

23 окт 2023 07:12:53 Источник Nasdaq GlobeNewswire

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

03 окт 2023 11:05:08 Источник Nasdaq GlobeNewswire

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

29 сен 2023 01:46:00 Источник Nasdaq GlobeNewswire